Inbrain Neuroelectronics, MINIGRAPH Consortium Build Robotic Implantation for Graphene BCIs

Inbrain Neuroelectronics and the MINIGRAPH consortium are developing a robotic implantation method for their ultra-thin graphene-based brain-computer interfaces, a step aimed at turning a fragile, investigational cortical technology into something a surgical team can deploy reproducibly.

The partnership targets the core practical bottleneck for thin-film neural interfaces: getting an ultra-thin, flexible graphene device onto or into cortical tissue without damaging either the implant or the brain. Robotic insertion systems have already proven the concept in human applications with flexible electrode arrays, and the consortium is now adapting that playbook to graphene microelectrodes, whose extreme thinness makes manual handling impractical at scale.

What is the device?

Inbrain's platform is built on graphene microelectrodes — carbon-based, atomically thin conductive elements patterned onto flexible substrates. Compared with conventional intracranial electrodes made of platinum-iridium or other metals, graphene offers low impedance and mechanical compliance that conforms to cortical tissue. The company positions these arrays as recording and stimulation interfaces for chronic implantation.

All of this work remains investigational. No graphene-based BCI from Inbrain carries FDA clearance or CE marking for human clinical use, and the announcement describes a development program, not a market-ready surgical product.

Why does robotic implantation matter?

For reading-room and monitoring-unit readers, the relevance is straightforward: device placement variability is one of the largest confounds in intracranial EEG interpretation. An electrode array that a robot inserts at controlled speed, angle and depth offers:

• Reproducible cortical coverage across patients and sessions
• Reduced mechanical trauma to tissue and to the ultra-thin film itself
• A standardized implantation protocol suitable for multi-center trials
• Shorter surgical times if the workflow matures

Flexible, ultra-thin arrays are difficult to insert manually because they buckle under their own force; robotic drivers solve this by advancing the device at constant velocity, sometimes with temporary stiffening structures or shuttles. That is the engineering problem the consortium's robotic system addresses.

Who is MINIGRAPH?

The MINIGRAPH consortium is a European collaborative research program named for its mission of advancing graphene-based neural interfaces. Its members span academic groups and industry partners, with Inbrain Neuroelectronics — a Barcelona-based spinout with deep roots in graphene neural technology — acting as the industrial anchor for translation. Consortium projects of this type typically combine materials science, microfabrication, electrophysiology validation and now surgical automation under one funded umbrella.

How should clinicians read this?

The announcement is preclinical development news. It concerns surgical delivery hardware for an implant class that has not yet completed human clinical trials, so it changes nothing in current epilepsy monitoring, intraoperative ECoG practice or implanted device follow-up today.

What it signals is trajectory. Robotic implantation is the manufacturing-grade step that separates laboratory prototypes from devices that can be implanted consistently across many patients — the prerequisite for any future first-in-human study of graphene cortical arrays. Clinicians who track intracranial device approvals will want to watch for the first regulatory submissions for human implantation of graphene electrodes, which this robotic delivery work is designed to enable.

The next milestone to watch is preclinical validation of the robotic insertion workflow — insertion-force testing, recording yield of the implanted graphene arrays, and biocompatibility data — before any human application can be proposed to regulators.